Pfizer and BioNTech Report Mixed Results in Phase 3 Flu-COVID Vaccine Trial
The vaccine candidate showed strong responses against influenza A and COVID-19 but did not meet its goal for influenza B.
The vaccine candidate showed strong responses against influenza A and COVID-19 but did not meet its goal for influenza B.
A new study has found that SARS-CoV-2 mRNA vaccination induces an immune response in the mucosal lining of the nasal cavity, offering new insights into potential vaccine strategies in the future.
A multidisciplinary team of Weill Cornell Medicine researchers have received a five-year $5.7 million grant from the National Cancer Institute at the National Institutes of Health to fund a center aimed at developing messenger RNA (mRNA) vaccines to deter cancer development in at-risk groups.